Cecilia Monge1, Erica C Pehrsson2,3,4, Changqing Xie1, Austin G Duffy1, Donna Mabry1, Bradford J Wood5, David E Kleiner6, Seth M Steinberg7, William D Figg8, Bernadette Redd9, Anuradha Budhu2,10, Sophie Wang1, Mayank Tandon3,4, Lichun Ma10, Xin Wei Wang2,10, Tim F Greten1,2. 1. Gastrointestinal Malignancies Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 2. Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 3. CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 4. Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 5. Center for Interventional Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 6. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 7. Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 8. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 9. Radiology and Imaging Sciences, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 10. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: We conducted a phase II study of the combination of pembrolizumab with capecitabine and oxaliplatin (CAPOX) in patients with advanced biliary tract carcinoma (BTC) to assess response rate and clinical efficacy. Exploratory objectives included correlative studies of immune marker expression, tumor evolution, and immune infiltration in response to treatment. PATIENTS AND METHODS: Adult patients with histologically confirmed BTC were enrolled and received oxaliplatin and pembrolizumab on day 1 of cycles 1-6. Capecitabine was administered orally twice daily as intermittent treatment, with the first dose on day 1 and the last dose on day 14 of cycles 1-6. Starting on cycle 7, pembrolizumab monotherapy was continued until disease progression. The primary endpoint was progression-free survival (PFS). Secondary endpoints were safety, tolerability, feasibility, and response rate. Immunohistochemistry (IHC) for PD-L1 and immune infiltrates was analyzed in paired tumor biopsies, as well as bulk transcriptome and exome profiling for five patients and single-cell RNA sequencing for one partial responder. RESULTS: Eleven patients enrolled, three of whom had received no prior systemic therapy. Treatment was well tolerated, and the most common treatment-related grade 3 or 4 adverse events were lymphocytopenia, anemia, and decreased platelet count. Three patients (27.3%) achieved a partial response, and six (54%) had stable disease. The disease control rate was 81.8%. The median PFS was 4.1 months with a 6-month PFS rate of 45.5%. Molecular profiling suggests qualitative differences in immune infiltration and clonal evolution based on response. CONCLUSION: Capecitabine and oxaliplatin in combination with pembrolizumab is tolerable and a potentially effective treatment for refractory advanced BTC. This study highlights a design framework for the precise characterization of individual BTC tumors. TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03111732). Published by Oxford University Press 2022.
BACKGROUND: We conducted a phase II study of the combination of pembrolizumab with capecitabine and oxaliplatin (CAPOX) in patients with advanced biliary tract carcinoma (BTC) to assess response rate and clinical efficacy. Exploratory objectives included correlative studies of immune marker expression, tumor evolution, and immune infiltration in response to treatment. PATIENTS AND METHODS: Adult patients with histologically confirmed BTC were enrolled and received oxaliplatin and pembrolizumab on day 1 of cycles 1-6. Capecitabine was administered orally twice daily as intermittent treatment, with the first dose on day 1 and the last dose on day 14 of cycles 1-6. Starting on cycle 7, pembrolizumab monotherapy was continued until disease progression. The primary endpoint was progression-free survival (PFS). Secondary endpoints were safety, tolerability, feasibility, and response rate. Immunohistochemistry (IHC) for PD-L1 and immune infiltrates was analyzed in paired tumor biopsies, as well as bulk transcriptome and exome profiling for five patients and single-cell RNA sequencing for one partial responder. RESULTS: Eleven patients enrolled, three of whom had received no prior systemic therapy. Treatment was well tolerated, and the most common treatment-related grade 3 or 4 adverse events were lymphocytopenia, anemia, and decreased platelet count. Three patients (27.3%) achieved a partial response, and six (54%) had stable disease. The disease control rate was 81.8%. The median PFS was 4.1 months with a 6-month PFS rate of 45.5%. Molecular profiling suggests qualitative differences in immune infiltration and clonal evolution based on response. CONCLUSION: Capecitabine and oxaliplatin in combination with pembrolizumab is tolerable and a potentially effective treatment for refractory advanced BTC. This study highlights a design framework for the precise characterization of individual BTC tumors. TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03111732). Published by Oxford University Press 2022.
Authors: Changqing Xie; Austin G Duffy; Donna Mabry-Hrones; Bradford Wood; Elliot Levy; Venkatesh Krishnasamy; Javed Khan; Jun S Wei; David Agdashian; Manoj Tyagi; Vineela Gangalapudi; Suzanne Fioravanti; Melissa Walker; Victoria Anderson; David Venzon; William D Figg; Milan Sandhu; David E Kleiner; Maria Pia Morelli; Charalampos S Floudas; Gagandeep Brar; Seth M Steinberg; Firouzeh Korangy; Tim F Greten Journal: Hepatology Date: 2019-03-10 Impact factor: 17.425
Authors: Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras Journal: Bioinformatics Date: 2012-10-25 Impact factor: 6.937
Authors: Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores Journal: Nat Rev Clin Oncol Date: 2017-10-10 Impact factor: 66.675
Authors: David M Kurtz; Mohammad S Esfahani; Florian Scherer; Joanne Soo; Michael C Jin; Chih Long Liu; Aaron M Newman; Ulrich Dührsen; Andreas Hüttmann; Olivier Casasnovas; Jason R Westin; Matthais Ritgen; Sebastian Böttcher; Anton W Langerak; Mark Roschewski; Wyndham H Wilson; Gianluca Gaidano; Davide Rossi; Jasmin Bahlo; Michael Hallek; Robert Tibshirani; Maximilian Diehn; Ash A Alizadeh Journal: Cell Date: 2019-07-04 Impact factor: 41.582
Authors: Jittiporn Chaisaingmongkol; Anuradha Budhu; Hien Dang; Siritida Rabibhadana; Benjarath Pupacdi; So Mee Kwon; Marshonna Forgues; Yotsawat Pomyen; Vajarabhongsa Bhudhisawasdi; Nirush Lertprasertsuke; Anon Chotirosniramit; Chawalit Pairojkul; Chirayu U Auewarakul; Thaniya Sricharunrat; Kannika Phornphutkul; Suleeporn Sangrajrang; Maggie Cam; Ping He; Stephen M Hewitt; Kris Ylaya; Xiaolin Wu; Jesper B Andersen; Snorri S Thorgeirsson; Joshua J Waterfall; Yuelin J Zhu; Jennifer Walling; Holly S Stevenson; Daniel Edelman; Paul S Meltzer; Christopher A Loffredo; Natsuko Hama; Tatsuhiro Shibata; Robert H Wiltrout; Curtis C Harris; Chulabhorn Mahidol; Mathuros Ruchirawat; Xin W Wang Journal: Cancer Cell Date: 2017-06-22 Impact factor: 31.743
Authors: Shiva Kumar R Mukkamalla; Hussain M Naseri; Byung M Kim; Steven C Katz; Vincent A Armenio Journal: J Natl Compr Canc Netw Date: 2018-04 Impact factor: 11.908
Authors: Peng Jiang; Shengqing Gu; Deng Pan; Jingxin Fu; Avinash Sahu; Xihao Hu; Ziyi Li; Nicole Traugh; Xia Bu; Bo Li; Jun Liu; Gordon J Freeman; Myles A Brown; Kai W Wucherpfennig; X Shirley Liu Journal: Nat Med Date: 2018-08-20 Impact factor: 53.440